Effect of Dialysis Techniques on Blood Pressure and Cardiac Function During Dialysis

Hemodialysis Clinical Trial

— HOLLANT  

Official title:

Effect of High-volume Online hemodiafiLtration on Intra-diaLytic hemodynAmic (iN)sTability and Cardiac Function in Chronic Hemodialysis Patients (the HOLLANT Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03249532
• Other study ID #: ABR 61210
• Status: Completed
• Phase: N/A
• Start date: June 1, 2018
• Est. completion date: February 15, 2021

Study information

• Verified date: November 2021
• Source: VU University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Online hemodiafiltration confers a reduced mortality risk. However, it is not clear why HDF improved survival. To gain more insight in this issue, the effect of 4 dialysis techniques (differing in dialysate temperature and the absence/presence of convective clearance) on intradialytic hemodynamic stability and cardiac function will be investigated in a prospective cross over trial.

Description:

Despite the use of high permeable dialyzers, which combine diffusive with convective clearance, the clinical outcome of hemodialysis (HD) patients remains poor. In post-dilution online hemodiafiltration (denoted further on as HDF) diffusive clearance is similar to HD, while the amount of convective transport is considerable increased. Recently, 4 randomized controlled trails have been published which compared HD with HDF. Although the results of the individual studies were inconclusive, a recent meta-analysis, using individual patient data of these studies, showed a superior outcome for patients treated with HDF. The largest mortality reduction was obtained in patients receiving the highest convection volume (high-volume HDF [HV-HDF] >23 L/1.73 m2/session): all-cause mortality [22% (95 % confidence interval [CI] 2-38)], cardiovascular disease (CVD) mortality [31% (95 % CI 0-53)]. It is far from clear, however, why (HV)HDF is associated with an improved survival. Both long term and short term effects may be involved. With respect to the latter, the intra-dialytic removal of middle molecular weight (MMW) uremic retention products and a superior bio-incompatibility (BI) profile may play a role. In addition, treatment with HDF may induce less intra-dialytic hypotension (IDH) and less tissue injury. Enhanced removal of the MMW substance FGF23 may reduce the intra-dialytic acute phase reaction (APR), which is regarded a chief element of HD-induced BI. Other key components which may contribute to IDH and are supposed to be alleviated by HDF, include dialysis-induced hypoxia and intra-dialytic extracellular vesicle release. Patho-physiologically, IDH depends both on a decline in the circulating blood volume and an impaired response to hypovolaemia. As a result, venous return, cardiac output and peripheral vascular resistance are impaired. Since IDH is reduced by HD with cool dialysate (C-HD), thermal factors may play an important role. Microcirculatory dysfunction is a prominent feature of HD patients. Since IDH occurs in 20-30% of the sessions, any interference with an already abnormal perfusion may further deteriorate the structure and function of vital organs, such as the brain, gut and heart. HD-associated cardiomyopathy, which is considered a model of repetitive organ ischemia-reperfusion injury, is superimposed on the cardiac changes resulting from the various inflammatory and metabolic derangements of pre-dialysis kidney disease. As measured by imaging techniques and biomarkers, HD induces a fall in cardiac perfusion and elicits tissue injury. While cardiac MRI is considered the reference method for LV quantification, intra-dialytic measurements can only be obtained in stable patients who can be safely transferred to the radiology department. Echocardiography, though, can be performed in all individuals at the bed-side, including hypotension-prone patients. Because of its superiority over standard echocardiography, especially with respect to diastolic (dys)function, speckle tracking echocardiography will be used in the present study. As mentioned, the effect on long term survival is especially prominent when HV-HDF is applied. Theoretically, HV-HDF is also the preferred treatment to circumvent dialysis-induced IDH, and hence, to alleviate the repetitive intra-dialytic tissue damage. Therefore, the following hypotheses will be tested: 1. intra-dialytic hemodynamic stability is better preserved during HV-HDF as compared to standard (S)-HD, C-HD and low volume (LV)-HDF; 2. mainly as a result of a better intra-dialytic hemodynamic stability, the severity of organ injury, especially the heart, is least evident during HV-HDF; 3. the mechanism of a better preserved intra-dialytic hemodynamic stability during HV-HDF depends on its superior thermal balance and/or bio-incompatibility, clearance of MMW substances, or a combination of these items. Worldwide, however, (HV)HDF is only limited available. Since intradialytic hemodynamic instability may contribute substantially to the poor clinical prospects of end-stage-kidney-disease (ESKD) patients, these individuals may benefit from each maneuver that minimizes the number and severity of intradialytic hypotensive episodes. Therefore, the question which of the comparator treatments [(S)-HD, C-HD and LV-HDF] has the best intradialytic hemodynamic stability, appears relevant as well.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: February 15, 2021
• Est. primary completion date: February 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• treatment with HD or HDF 3 x per week during at least 4 hours for at least 2 months
• ability to understand study procedures
• willingness to provide informed consent
• single pool Kt/V urea (spKt/Vurea) = 1.2
• achievement of blood flow of =360 ml/min and/or convection volume of >23 Liter per treatment during the run-in phase

Exclusion Criteria:

• - current age < 18 years
• severe incompliance to dialysis procedure and accompanying prescriptions, especially frequency and duration of dialysis treatment
• life expectancy < 3 months
• participation in another clinical intervention trial

Related Conditions & MeSH terms

• Diastolic Dysfunction
• End Stage Renal Disease (ESRD)
• Hemodiafiltration
• Hemodialysis
• Hypotension
• Intradialytic Hypotension
• Kidney Failure, Chronic

Intervention

Device:
• standard hemodialysis
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
• cool hemodialysis
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
• low volume hemodiafiltration
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
• high volume hemodiafiltration
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L

Locations

Country	Name	City	State
Netherlands	Niercentrum aan de Amstel	Amstelveen
Netherlands	VUmc	Amsterdam
Netherlands	St Antonius Ziekenhuis	Nieuwegein	Utrecht

Sponsors (3)

Lead Sponsor	Collaborator
VU University Medical Center	B.Braun Avitum AG, Niercentrum aan de Amstel, Amstelveen, Netherlands

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	systolic blood pressure	change in systolic blood pressure (mmHg)	up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
Other	diastolic blood pressure	change in diastolic blood pressure (mmHg)	up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
Other	mean arterial blood pressure	change in mean arterial blood pressure (mmHg)	up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
Other	pulse pressure	change in pulse pressure (systolic - diastolic blood pressure; mmHg)	up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
Other	beat-to-beat blood pressure	change in beat-to-beat blood pressure (finger cuff; mmHg)	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	heart rate	change in heart rate (finger cuff assessment)	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	stroke volume	change in stroke volume (finger cuff assessment)	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	cardiac output	change in cardiac output (finger cuff assessment)	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	total peripheral resistance	change in total peripheral resistance (finger cuff assessment)	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	number of sessions with reached target dry weight	number of sessions with reached target dry weight (kg)	up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
Other	relative blood volume	relative blood volume (%) during dialysis treatment	up to 4 hours(= one dialysis treatment); assessed during 2 treatments on each modality
Other	oxygen saturation	oxygen saturation in the arterial line of the extracorporeal system (%) during dialysis treatment; patients with central venous catheters and fistulas/grafts will be analyzed separately	up to 4 hours(= one dialysis treatment); assessed during 2 treatments on each modality
Other	oxygen partial pressure (pO2)	pO2 in the arterial line of the extracorporeal system (mmHg or kiloPascal [kPa], assessed by a point of care device) during dialysis treatment; patients with central venous catheters and fistulas/grafts will be analyzed separately	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	change in creatine kinase (CK)-MB	marker of cardiac damage, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	change in bacterial DNA in blood	marker of gut ischemia, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	change in soluble CD14	marker of gut ischemia, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	change in extracellular vesicles (EVs)	marker of endothelial damage, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	change in soluble intercellular adhesion molecule-1 (s-ICAM-1)	marker of endothelial damage, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	change in high sensitivity C-reactive protein (hs-CRP)	marker of inflammation, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	change in interleukin-6 (IL-6)	marker of inflammation, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Other	change in fibroblast growth factor-23 (FGF-23)	marker of inflammation/mineral bone disease, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment	up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
Primary	intradialytic hypotension	nadir in systolic blood pressure (SBP) of 90 mmHg for patient with predialysis SBP <160mmHg and a nadir of 100 mmHg for patients with predialysis SBP =160 mmHg during treatment (blood pressure will be measured before and every 15 minutes after the start of dialysis during the treatment)	up to 4 hours (= one dialysis treatment); assessed during 3 treatments on each modality
Secondary	diastolic dysfunction during treatment	speckle tracking echocardiography will be performed before, after 60 minutes of dialysis and after and after 3,5 hours	up to 4 hours (= one dialysis treatment); assessed during 1 treatment on each modality